Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) FCF Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed FCF Margin for 3 consecutive years, with 2302.46% as the latest value for Q2 2025.

  • On a quarterly basis, FCF Margin rose 5414354.0% to 2302.46% in Q2 2025 year-over-year; TTM through Sep 2025 was 11125.52%, a 785068.0% increase, with the full-year FY2024 number at 98503.0%, down 8773478.0% from a year prior.
  • FCF Margin was 2302.46% for Q2 2025 at Inhibrx Biosciences, down from 1335.66% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1335.66% in Q1 2025 to a low of 56446.0% in Q2 2024.
  • A 3-year average of 14731.8% and a median of 2302.46% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -4029726bps in 2024, then skyrocketed 5414354bps in 2025.
  • Inhibrx Biosciences' FCF Margin stood at 3438.74% in 2023, then plummeted by -1172bps to 43736.0% in 2024, then soared by 95bps to 2302.46% in 2025.
  • Per Business Quant, the three most recent readings for INBX's FCF Margin are 2302.46% (Q2 2025), 1335.66% (Q1 2025), and 43736.0% (Q4 2024).